RPRX

Royalty Pharma Stock Analysis

AI Rating

Low
  • Quality9/10
  • Growth↓ 1/10
  • Value↓ 1/10
Royalty Pharma sales and earnings growth
RPRX Growth
Low
  • Revenue Y/Y↑ 5.06%
  • EPS Y/Y↓ -6.77%
  • FCF Y/Y↓ -17.65%
Royalty Pharma gross and profit margin trends
RPRX Profitability
Good
  • Gross margin ↑ 100.00%
  • EPS margin↑ 32.40%
  • ROIC 5Y↓ 4.30%
Royalty Pharma recent dividend growth
RPRX Dividends
  • Dividend yield 2.02%
  • Growth 3Y↑ 4.88%
  • Payout ratio↑ 49%
Royalty Pharma net debt vs free cash flow
RPRX Risk
Great
  • Debt / Equity↓ 0.9
  • Debt / FCF↓ 3.8
  • Interest coverage↓ 3.5

Royalty Pharma stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗